<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04602767</url>
  </required_header>
  <id_info>
    <org_study_id>20D.847</org_study_id>
    <nct_id>NCT04602767</nct_id>
  </id_info>
  <brief_title>Low Dose Vasopressin vs Phenylephrine in Cardiac Surgery</brief_title>
  <official_title>Low Dose Vasopressin vs Phenylephrine in Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open label study to investigate vasopressin versus phenylephrine as a&#xD;
      first line pressor in cardiac surgery. All patients &gt;18 years of age presenting for coronary&#xD;
      artery bypass graft (CABG), valve surgery, or combined CABG and valve surgery will be&#xD;
      screened for inclusion. Patients with ejection fraction &lt; 35%, &gt; moderate pulmonary&#xD;
      hypertension, &gt; mild right ventricular dysfunction, a planned radial arterial graft, or&#xD;
      circulatory arrest will be excluded. Patients will be randomized to receive either&#xD;
      vasopressin or phenylephrine as the first line vasopressor during the perioperative period to&#xD;
      maintain mean arterial blood pressure &gt;65 mmhg. Primary outcome is acute kidney injury.&#xD;
      Secondary outcomes are 30-day mortality, stroke, myocardial infarction, re-operation, sternal&#xD;
      infection, atrial fibrillation, intensive care unit length of stay, and total vasopressor&#xD;
      hours.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute Kidney Injury</measure>
    <time_frame>5 Days</time_frame>
    <description>KDIGO criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>30-Day Mortality</measure>
    <time_frame>30 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reoperation</measure>
    <time_frame>5 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sternal Infection</measure>
    <time_frame>5 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial Fibrilation</measure>
    <time_frame>5 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU Length of Stay</measure>
    <time_frame>5 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Vasopressor Hours</measure>
    <time_frame>5 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>Vasopressin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose vasopressin as first line vasopressor in cardiac surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phenylepherine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose phenylephrine as first line vasopressor in cardiac surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vasopressin</intervention_name>
    <description>Vasopressin titrated 0.01 U/min up to 0.04 U/min for MAP &lt; 65 mmHg</description>
    <arm_group_label>Vasopressin</arm_group_label>
    <other_name>Pitressin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenylephrine</intervention_name>
    <description>Phenylephrine titrated 0.25 mcg/kg/min up to 1.0 mcg/kg/min for MAP &lt; 65 mmHg</description>
    <arm_group_label>Phenylepherine</arm_group_label>
    <other_name>Neosynephrine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients &gt;18 years of age presenting for coronary artery bypass graft (CABG),&#xD;
             valve surgery, or combined CABG and valve surgery will be screened for inclusion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with ejection fraction &lt; 35%, &gt; moderate pulmonary hypertension, &gt; mild right&#xD;
             ventricular dysfunction, a planned radial arterial graft, or circulatory arrest will&#xD;
             be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jenifer Lessin</last_name>
    <phone>215 955-5804</phone>
    <email>jennifer.lessin@jefferson.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Thomas Jefferson Univesity</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordan Goldhammer, MD</last_name>
      <email>jordan.goldhammer@jefferson.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 20, 2020</study_first_submitted>
  <study_first_submitted_qc>October 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2020</study_first_posted>
  <last_update_submitted>October 20, 2020</last_update_submitted>
  <last_update_submitted_qc>October 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Thomas Jefferson University</investigator_affiliation>
    <investigator_full_name>Jordan Goldhammer</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Vasopressins</mesh_term>
    <mesh_term>Arginine Vasopressin</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

